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original article

Attributable Inpatient Costs of Recurrent
Clostridium difficile Infections
Erik R. Dubberke, MD, MSPH;1 Eric Schaefer, MS;2 Kimberly A. Reske, MPH;1
Marya Zilberberg, MD, MPH;3 Christopher S. Hollenbeak, PhD;4
Margaret A. Olsen, PhD, MPH1,5

objective. To determine the attributable inpatient costs of recurrent Clostridium difficile infections (CDIs).
design.

Retrospective cohort study.

setting. Academic, urban, tertiary care hospital.
patients. A total of 3,958 patients aged 18 years or more who developed an initial CDI episode from 2003 through 2009.
methods. Data were collected electronically from hospital administrative databases and were supplemented with chart review. Patients
with an index CDI episode during the study period were followed up for 180 days from the end of their index hospitalization or the end
of their index CDI antibiotic treatment (whichever occurred later). Total hospital costs during the outcome period for patients with recurrent
versus a single episode of CDI were analyzed using zero-inflated lognormal models.
results. There were 421 persons with recurrent CDI (recurrence rate, 10.6%). Recurrent CDI case patients were significantly more
likely than persons without recurrence to have any hospital costs during the outcome period (P ! .001). The estimated attributable cost
of recurrent CDI was $11,631 (95% confidence interval, $8,937–$14,588).
conclusions. The attributable costs of recurrent CDI are considerable. Patients with recurrent CDI are significantly more likely to
have inpatient hospital costs than patients who do not develop recurrences. Better strategies to predict and prevent CDI recurrences are
needed.
Infect Control Hosp Epidemiol 2014;35(11):1400-1407

Clostridium difficile infection (CDI) is a formidable challenge.
Although most cases of CDI are successfully treated, 10%–
30% of patients experience a CDI recurrence.1,2 There are
relatively few published studies that specifically examine recurrent CDI. A number of risk factors for recurrent CDI have
been reported, most commonly older age,1,3-10 higher severity
of illness,4,6 hospitalization after initial CDI,10,11 receipt of antibiotics during the period after initial CDI,1,3,4,6,7,11,12 and receipt of antacids.1,3,7,13 In addition, Pepin et al9 and Petrella
et al14 have reported increased recurrence rates associated with
the 027/NAP1/BI strain.
Data on the economic burden of recurrent CDI on the
healthcare system are extremely sparse. McFarland et al8 have
published the only estimates of costs associated with recurrent
CDI, estimating that recurrent CDI costs $3,103 per episode
and $10,970 over a patient’s lifetime. While these estimates
are the best data currently available, they predate the emer-

gence of the 027/NAP1/BI strain and do not estimate the
attributable costs associated with recurrent CDI. The objective of this study was to determine the attributable inpatient
costs of recurrent CDI in a large retrospective cohort of CDI
patients.

methods
Study Design
This study was conducted at Barnes-Jewish Hospital (BJH),
an academic tertiary care facility in St. Louis, Missouri. Data
were collected electronically from the hospital’s electronic
medical records and from the Medical Informatics and
Trendstar financial databases. The Informatics database was
queried to identify all patients with positive C. difficile toxin
assay results collected from January 1, 2003, through December 31, 2009. The BJH laboratory accepts only diarrheal stool
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samples for C. difficile testing. Two toxin assays were used
during the study period (TechLab C. difficile Toxin A/B II
before July 2004 and again after May 2009; Remel ProSpec
T C. difficile A/B from July 2004 through May 2009). Additional electronic data included demographics, admission
and discharge dates, admission type (eg, inpatient, outpatient,
or emergency department), International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis and procedure codes, inpatient medications, and laboratory results. In addition, medical records were reviewed
to identify medications on hospital admission and discharge
and whether the patient received a diagnosis of recurrent CDI.
Total hospital costs (direct, indirect, and fixed) and major
diagnostic category (MDC) codes were collected from Trendstar. Death dates were collected from the Informatics database
and the Social Security Death Index. ICD-9-CM discharge
codes from the index admission and any admissions within
the previous year were classified according to Charlson-Deyo
categories.15,16
Definitions
A CDI index hospitalization was defined as the first inpatient
hospitalization during the study period in which the patient
had a positive C. difficile toxin assay. All index CDI cases had
a positive toxin assay at BJH. The outcome period was defined
as 180 days after the end of the index hospitalization or the
end of the patient’s index CDI antibiotic treatment, whichever
occurred later. A recurrent CDI case was defined as a patient
who had documentation of recurrent CDI within 42 days of
the end of CDI antibiotic treatment, either by positive toxin
assay or by clinical diagnosis documented in the medical
record (history of a positive laboratory test as an outpatient
or at an outside healthcare facility and symptoms consistent
with CDI). We used 42 days as the risk period to develop
recurrent CDI on the basis of the current surveillance definition of 8 weeks (ie, 56 days) between episodes to be considered recurrent CDI.17 Since the recommended CDI treatment duration is 10–14 days,18 the risk period for recurrent
CDI after the end of treatment using the surveillance definition is 42–46 days. Patients were included in the study only
once.
Exclusion Criteria
Patients who were less than 18 years old, had a documented
history of CDI (either by positive toxin assay or recorded in
the medical record) in the 60 days before the study period,
or were admitted for less than 0.75 days during their index
CDI admission were excluded. Patients who experienced a
CDI recurrence during the index hospitalization were also
excluded because of the difficulty in separating costs associated with each CDI episode. Patients who died during their
index hospitalization or were discharged on hospice were
excluded. Readmissions that began during the 180-day outcome period but ended after the 180-day outcome period
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were excluded. For readmissions that began prior to the outcome period, costs were prorated to include only those days
that occurred within the outcome period.
Statistical Analyses
The total hospital cost during the outcome period was defined
as the cumulative sum of all costs for hospital readmissions
during the 180-day outcome period. All hospital readmission
costs were inflated to 2010 dollars based on the year of discharge using the medical care component of the consumer
price index.
Zero-inflated lognormal models were used to identify factors associated with total hospital readmission costs during
the outcome period because 55% of patients had no readmissions during the 180-day outcome period and thus no
readmission costs.19 The models had 2 components: a logistic
regression component modeling the probability of zero costs
(ie, no readmissions during the outcome period), and a lognormal regression component modeling the mean of log costs
given nonzero costs (ie, 1 or more readmissions during the
outcome period). Cost data were normally distributed after
log transformation.
Two models were fitted. The first model included only
recurrent CDI status. The full model included recurrent CDI
status and other relevant covariates. Missing body mass index
(BMI) values (n p 31; 0.8%) were imputed at the median
of 26. All covariates were included in both components of
the model.
Odds ratios (ORs) were calculated for the logistic component and cost ratios (CRs) were calculated for the lognormal component for all covariates in the model, with corresponding 95% confidence intervals (CI). Quartiles of age
were used in the model since exploratory graphical methods
and spline fits indicated nonlinear associations, especially for
the lognormal component. All other variables were categorical. The quasi-maximum-likelihood estimator was used to
back-transform log costs to actual dollar costs.20
Overall mean costs were calculated by multiplying the estimated probability of nonzero cost from the logistic model
times the expected cost from the lognormal portion of the
model. Differences in overall mean costs between exposures
(eg, recurrent CDI vs no recurrent CDI) were calculated using
the average predicted value (APV) method.21 The APV
method is useful to understand how overall mean costs differ
by covariates, regardless of the mechanism(s) by which the
differences may arise. The APV method was applied by calculating predicted costs from the fitted model for both levels
of the variable of interest (eg, recurrent CDI vs no recurrent
CDI) separately for all patients in the data set. Then, the
mean difference was calculated across all patients. The
method was applied separately for all covariates in the model
to obtain differences in overall mean costs for all covariates.
Bootstrapping (500 samples) and the percentile method were
used to calculate 95% CIs. The difference in overall mean
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table 1. Percentages of Zero and Nonzero Costs by All Variables
Variable
Recurrent CDI
No recurrent CDI
Age quartile
!49 years
49 to !62 years
62 to !74 years
≥74 years
Sex
Female
Male
Race
White
Nonwhite
Body mass index
Missing
Underweight
Normal weight
Overweight
Obese
Charlson composite score
0
1
2
3
4
≥5
Charlson comorbidities
Myocardial infarction
Congestive heart failure
Peripheral vascular disease
Cerebrovascular disease
Chronic renal failure
Dementia
Chronic obstructive pulmonary disease
Rheumatologic disease
Peptic ulcer disease
Any liver disease
Any diabetes
Paraplegia/hemiplegia
Cancer (excluding leukemia/lymphoma)
Leukemia/lymphoma
Metastatic solid tumor
HIV/AIDS
MDC
0 (unassigned principal diagnosis)
1 (diseases of the nervous system)
4 (diseases of the respiratory system)
5 (diseases of the circulatory system)
6 (diseases of the digestive system)
7 (diseases of the hepatobiliary system and pancreas)
8 (diseases of the musculoskeletal system and connective tissue)
10 (endocrine, nutritional, and metabolic diseases)
11 (diseases of the kidney and urinary tract)
13 (diseases of the female reproductive system)
16 (diseases of blood, blood-forming organs, immunologic)
17 (myeloproliferative diseases)
18 (infectious and parasitic diseases)
21 (injuries, poisonings, toxic effects of drugs)
25 (HIV infections)
All others

Zero cost, no. (%)

Nonzero cost, no. (%)

Total (n p 3,958)

45 (10.7)
2,111 (59.7)

376 (89.3)
1,426 (40.3)

421
3,637

485
537
530
604

(50.8)
(52.1)
(54.6)
(60.3)

470
493
441
398

(49.2)
(47.9)
(45.4)
(39.7)

955
1,030
971
1,002

1,069 (55.8)
1,087 (53.2)

846 (44.2)
956 (46.8)

1,915
2,043

1,529 (56.2)
627 (50.7)

1,192 (43.8)
610 (49.3)

2,721
1,237

29
169
745
592
621

(93.5)
(53.1)
(53.1)
(53.2)
(56.8)

2
149
658
520
473

(6.5)
(46.9)
(46.9)
(46.8)
(43.2)

31
318
1,403
1,112
1,094

439
391
529
263
125
409

(65.5)
(61.6)
(53.9)
(51.2)
(45.3)
(46.4)

231
244
452
251
151
473

(34.5)
(38.4)
(46.1)
(48.8)
(54.7)
(53.6)

670
635
981
514
276
882

161
449
156
151
83
15
524
87
92
107
521
43
404
299
236
26

(48.2)
(50.8)
(53.8)
(54.3)
(41.1)
(53.6)
(54.2)
(55.8)
(57.5)
(47.6)
(49.7)
(50.0)
(50.6)
(43.5)
(50.3)
(35.1)

173
434
134
127
119
13
443
69
68
118
527
43
395
389
233
48

(51.8)
(49.2)
(46.2)
(45.7)
(58.9)
(46.4)
(45.8)
(44.2)
(42.5)
(52.4)
(50.3)
(50.0)
(49.4)
(56.5)
(49.7)
(64.9)

334
883
290
278
202
28
967
156
160
225
1,048
86
799
688
469
74

404
90
160
188
615
109
72
43
140
28
24
79
108
18
16
62

(60.4)
(60.8)
(52.3)
(51.6)
(58.8)
(56.5)
(55.4)
(46.2)
(49.6)
(70.0)
(36.9)
(33.8)
(49.3)
(56.3)
(42.1)
(62.6)

265
58
146
176
431
84
58
50
142
12
41
155
111
14
22
37

(39.6)
(39.2)
(47.7)
(48.4)
(41.2)
(43.5)
(44.6)
(53.8)
(50.4)
(30.0)
(63.1)
(66.2)
(50.7)
(43.8)
(57.9)
(37.4)

669
148
306
364
1,046
193
130
93
282
40
65
234
219
32
38
99

note. Row percentages are used. CDI, Clostridium difficile infection; HIV, human immunodeficiency virus; MDC, major diagnostic
category.
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table 2. Estimated Probabilities and Overall Mean Costs
Adjusted for Recurrent Clostridium difficile Infection (CDI)
Status Only
Recurrent
CDI
No
Yes

Probability of
zero cost

Expected
mean cost given
nonzero costs, $

Overall mean
costs,a $

0.597
0.107

20,964
21,942

8,448
19,594

Overall mean costs p (1 ⫺ probability of zero cost) # expected mean cost given nonzero cost.

a

cost between patients with recurrent CDI and patients without recurrent CDI was used as the measure for attributable
cost.
The data set included patients who died during the 180day outcome period. A sensitivity analysis was performed to
determine the effect of death on the final cost estimates for
recurrent CDI. The zero-inflated lognormal models were refit
to the data set excluding patients who died during the outcome period. The APV with bootstrapping was used to estimate attributable costs of recurrent CDI.
This study was approved by the Washington University
School of Medicine Human Research Protection Office. Statistical analyses were performed with SAS version 9.3 and R
version 3.0.1.

results
A total of 4,615 patients were evaluated for the study; 3,958
patients met the inclusion criteria and were included. The
CDI recurrence rate was 10.6% (n p 421). Of the 421 patients
with recurrent CDI, 302 (72%) had a positive toxin assay at
BJH. The study population consisted of 2 distinct subpopulations: patients with zero costs (ie, no readmissions) during
the outcome period (n p 2,156; 55%), and patients with
nonzero costs (ie, 1 or more readmissions) during the outcome period (n p 1,802; 45%; Table 1). Total hospital costs
for the subpopulation with nonzero costs were highly skewed,
with a median of $10,560 and a distribution that ranged from
$213 to $1,014,000 (interquartile range, $4,333–$23,980);
89% of recurrent CDI cases had nonzero costs (n p 376),
compared with 40% of patients without recurrent CDI (n p
1,426; P ! .001).
For the base regression model, which included only recurrent CDI status, the logistic portion of the model indicated
that the odds of zero costs (ie, no readmissions) for patients
with recurrent CDI were 0.08 (95% CI, 0.06–0.11; P ! .001)
compared with patients without recurrent CDI. The model
also indicated that, given nonzero total cost (ie, 1 or more
readmissions), patients with recurrent CDI had an average
of 5% larger total costs (CR, 1.05) than patients without
recurrent CDI (95% CI, 0.91–1.20; P p 0.52). Stated conversely, patients with recurrent CDI were 12.5 times more
likely to accrue any readmission costs (ie, be readmitted) than
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were patients without recurrent CDI. However, patients with
recurrent CDI who were readmitted had only 5% larger costs
than patients without recurrent CDI who were readmitted.
The expected probabilities of zero and nonzero costs and
the overall mean costs of recurrent CDI status are shown in
Table 2. Patients without recurrent CDI had a 0.597 probability
of zero costs, compared with a 0.107 probability for recurrent
CDI patients. For patients with recurrent CDI who had nonzero
costs, the expected mean cost was $21,942, and the expected
overall mean cost for recurrent CDI was $19,594; this value
includes both the probability of zero costs and the expected
mean cost given nonzero costs. The difference in overall mean
costs between groups was $11,146 ($19,594 ⫺ $8,448).
For the regression model that included recurrent CDI
status and adjustments for other demographic variables (“full
model”), recurrent CDI was significantly associated with
lower odds of zero costs (OR, 0.07 [95% CI, 0.05–0.10];
P ! .001) compared with patients without recurrent CDI
(Table 3). Nonwhite race, various MDC codes, and several
comorbidities were also associated with significantly lower
odds of zero cost. Increasing age was associated with higher
odds of zero cost.
For the subpopulation with nonzero costs, recurrent CDI
status was marginally associated (P p .07) with increased
costs (CR, 1.13 [95% CI, 0.99–1.30]). MDC codes 17 (myeloproliferative disease), 0 (not classified), 7 (hepatobiliary and
pancreas disease), and 18 (infectious and parasitic diseases)
were associated with increased costs relative to MDC code 6
(diseases of the digestive system; this was chosen as the reference category because it was the most commonly identified
MDC category in the data). Myocardial infarction, rheumatologic disease, and leukemia/lymphoma were also associated with increased costs. Older age (more than or equal
to 74 years) and cerebrovascular disease were associated with
decreased costs.
Differences in overall mean costs as estimated by the APV
method are shown in Figure 1. After adjusting for all other
variables in the model, older age was associated with lower
overall mean costs, while recurrent CDI was associated with
higher overall mean costs. After adjusting for age, sex, race,
BMI, MDC code, and comorbidities, the attributable cost of
recurrent CDI was $11,631 (95% CI, $8,937–$14,588).
Sensitivity analysis. Twenty-seven percent of the study
population (n p 1,065) died during the 180-day outcome
period. Patients who died were more likely to have nonzero
costs (52% vs 43%) and higher median costs ($14,618 vs
$9,255) than patients who survived for the full 180 days.
Patients with recurrent CDI were more likely to die during
the outcome period (36.6% vs 25.8%) than patients without
recurrent CDI. After adjusting for all demographic variables
in the data set that excluded individuals who died and after
applying the APV method, the attributable cost of recurrent
CDI was $8,709 (95% CI, $6,219–$11,529).

This content downloaded from 128.252.139.41 on Sat, 3 Jan 2015 15:39:01 PM
All use subject to JSTOR Terms and Conditions

1404

infection control and hospital epidemiology

november 2014, vol. 35, no. 11

table 3. Estimated Odds Ratios (ORs) and Cost Ratios (CRs) with 95% Confidence Intervals (CIs) from the Model That
Adjusted for All Variables
Variable
Recurrent CDI (vs none)
Age quartile
!49 years
49 to !62 years
62 to !74 years
≥74 years
Male (vs female)
Nonwhite (vs white)
Body mass index
Normal weight
Underweight
Overweight
Obese
MDC
6 (diseases of the digestive system)
0 (unassigned principal diagnosis)
1 (diseases of the nervous system)
4 (diseases of the respiratory system)
5 (diseases of the circulatory system)
7 (diseases of the hepatobiliary system and pancreas)
8 (diseases of the musculoskeletal system and connective tissue)
10 (endocrine, nutritional, and metabolic diseases)
11 (diseases of the kidney and urinary tract)
13 (diseases of the female reproductive system)
16 (diseases of blood, blood-forming organs, immunologic)
17 (myeloproliferative diseases)
18 (infectious and parasitic diseases)
21 (injuries, poisonings, toxic effects of drugs)
25 (HIV infections)
All others
Charlson comorbidities
Myocardial infarction
Congestive heart failure
Peripheral vascular disease
Cerebrovascular disease
Chronic renal failure
Dementia
Chronic obstructive pulmonary disease
Rheumatologic disease
Peptic ulcer disease
Any liver disease
Any diabetes
Paraplegia/hemiplegia
Cancer (excluding leukemia/lymphoma)
Leukemia/lymphoma
Metastatic solid tumor
HIV/AIDS
note.

OR (95% CI) for
zero cost

P

CR (95% CI) given
nonzero cost

P

0.07 (0.05–0.10)

!.001

1.13 (0.99–1.30)

.07

1.00
1.22
1.44
1.86
0.98
0.79

(reference)
(1.01–1.49)
(1.17–1.76)
(1.50–2.30)
(0.85–1.13)
(0.68–0.92)

.04
!.001
!.001
.83
.003

1.00
0.90
0.92
0.79
0.95
1.02

(reference)
(0.77–1.05)
(0.78–1.08)
(0.67–0.94)
(0.85–1.07)
(0.90–1.16)

.18
.32
.009
.41
.74

1.00
1.08
1.07
1.22

(reference)
(0.82–1.41)
(0.90–1.27)
(1.02–1.46)

.59
.46
.03

1.00
0.99
0.96
1.01

(reference)
(0.80–1.22)
(0.84–1.10)
(0.88–1.17)

.94
.60
.87

1.00
1.09
0.99
0.79
0.74
1.06
0.70
0.65
0.67
1.82
0.49
0.45
0.68
0.72
1.55
1.18

(reference)
(0.86–1.37)
(0.66–1.47)
(0.59–1.04)
(0.56–0.97)
(0.75–1.50)
(0.47–1.03)
(0.41–1.04)
(0.50–0.89)
(0.86–3.86)
(0.28–0.85)
(0.32–0.65)
(0.49–0.93)
(0.34–1.52)
(0.55–4.36)
(0.74–1.87)

.47
.95
.10
.03
.73
.07
.07
.006
.12
.01
!.001
.02
.39
.40
.48

1.00
1.49
1.55
1.26
1.12
1.48
1.14
1.21
1.16
1.24
1.18
2.25
1.30
1.29
1.15
0.98

(reference)
(1.23–1.81)
(1.11–2.18)
(1.00–1.58)
(0.90–1.40)
(1.12–1.97)
(0.82–1.58)
(0.86–1.71)
(0.93–1.45)
(0.63–2.43)
(0.80–1.73)
(1.74–2.91)
(1.02–1.67)
(0.69–2.41)
(0.58–2.25)
(0.66–1.45)

0.71
0.75
0.99
1.08
0.60
0.97
0.97
1.06
1.22
0.60
0.81
0.78
0.63
0.53
0.94
0.40

(0.54–0.92)
(0.63–0.90)
(0.75–1.30)
(0.80–1.46)
(0.44–0.83)
(0.40–2.33)
(0.82–1.15)
(0.74–1.52)
(0.85–1.75)
(0.44–0.81)
(0.69–0.95)
(0.48–1.26)
(0.50–0.79)
(0.42–0.67)
(0.71–1.23)
(0.18–0.87)

.009
.002
.95
.63
.002
.94
.75
.74
.27
!.001
.01
.31
!.001
!.001
.65
.02

1.23
1.13
1.22
0.77
1.02
1.39
1.00
1.45
1.04
1.15
1.08
0.96
0.96
1.37
0.98
1.17

(1.01–1.51)
(0.98–1.30)
(0.98–1.52)
(0.61–0.98)
(0.81–1.29)
(0.71–2.71)
(0.88–1.15)
(1.09–1.94)
(0.78–1.40)
(0.91–1.45)
(0.95–1.23)
(0.67–1.38)
(0.80–1.14)
(1.15–1.63)
(0.80–1.22)
(0.74–1.87)

!.001

.01
.05
.30
.006
.43
.28
.20
.54
.40
!.001
.04
.42
.69
.92
.04
.10
.07
.03
.85
.34
.96
.01
.77
.25
.23
.84
.62
!.001
.88
.50

CDI, Clostridium difficile infection; HIV, human immunodeficiency virus; MDC, major diagnostic category.

discussion
This study is the first to estimate the attributable inpatient
costs of recurrent CDI. Previous estimates by Dubberke et
al22 and Kyne et al23 of the attributable costs of any CDI per
hospitalization were between $2,400 and $3,700, but neither
of these studies included recurrent CDI. Dubberke et al22

estimated the attributable cost of CDI over the 180 days after
initial infection as $5,042–$7,179, and while this estimate
surely includes some of the costs associated with recurrence,
the analysis was not limited specifically to recurrent CDI
cases. As mentioned previously, only McFarland et al8 have
studied the costs associated with recurrent CDI; their esti-
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figure 1. Forest plots of overall mean differences in total costs (filled circles) with 95% confidence intervals (line segments) for each
covariate relative to the reference group. BMI, body mass index; CDI, Clostridium difficile infection; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; CRF, chronic renal failure; CVD, cerebrovascular disease; HIV, human immunodeficiency virus;
Leuk/lymph, leukemia/lymphoma; MDC, major diagnostic category; Mets, metastatic solid tumor; MI, myocardial infarction; PUD, peptic
ulcer disease; PVD, peripheral vascular disease; Rheum, rheumatologic disease.

mates were $3,103 per recurrent CDI episode and $10,970
over a patient’s lifetime ($4,152 per episode and $14,675 lifetime in 2010 dollars, assuming that McFarland et al’s estimates used 1998 dollars), but they did not determine attributable costs.
The estimated attributable inpatient costs of recurrent CDI
over the 180 days after the initial episode of CDI reported
in this study was $11,631 (95% CI, $8,937–$14,588). This
value reflects that patients with recurrent CDI would be expected to accrue about $11,000 more per patient, on average,
than those without recurrent CDI. This estimate is significantly larger than McFarland et al’s per-episode estimate of
$3,103 ($4,152 in 2010 dollars) and is comparable to their
lifetime estimate of $10,970 ($14,675 in 2010 dollars). These
estimates suggest that the attributable cost of recurrent CDI
has increased since publication of McFarland et al’s study in
1999. They were able to capture some outpatient costs (clinic

visits), whereas outpatient costs were not included in our
study. McFarland et al’s definition of “lifetime” costs was from
a patient’s first episode of CDI through enrollment into a
clinical trial of combination treatment for recurrent CDI (and
the next recurrence after enrollment); many patients were
followed up for more than 180 days. If outpatient costs had
been included in our current study and patients had been
followed up for a longer period of time, the attributable cost
of CDI would likely have been even larger.
The primary mechanism of the increased costs associated
with CDI recurrence was the increased probability of having
any costs (ie, being readmitted) during the outcome period
for patients with recurrent CDI. While the recurrent CDI
attributable cost estimate among patients with any costs (both
recurrent CDI and nonrecurrent CDI patients with nonzero
costs) during the outcome period was of borderline statistical
significance (P p .07), recurrent CDI patients were 12.5 times
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more likely to have any hospital costs than nonrecurrent CDI
patients. Recurrent CDI may have been the primary reason
for readmission, or recurrence may have occurred during a
readmission and prolonged or complicated the hospitalization. In either situation, recurrent CDI is a potentially modifiable factor that significantly increases inpatient costs.
Although recurrent CDI was associated with only marginally
increased hospital costs among all readmitted patients, since
recurrent CDI patients were much more likely to be readmitted
to the hospital, this translated to an attributable cost estimate
of $11,631 (95% CI, $8,937–$14,588) per patient. There were
421 recurrent CDI cases, so the total estimated attributable cost
of recurrent CDI would be $4,896,651 (95% CI, $3,762,477–
$6,141,548; 2010 dollars) for our single facility over the 7 years
examined in our study. These costs reflect only facility costs
and do not include provider charges. Furthermore, this estimate does not take into account other quality-of-life issues for
patients, such as loss of work, prescription drug costs, or increased morbidity due to recurrence.
The relationship among death, recurrent CDI, and cost
estimates is somewhat unclear. Patients who died during the
outcome period were necessarily followed up for less than
180 days, suggesting that the total costs were biased downward compared with those for patients followed up for the
full period. On the other hand, deaths are typically associated
with large hospital costs.24,25 In our analyses, patients with
recurrent CDI were more likely to die, and patients who died
were more likely to have nonzero costs. These two findings
indicated that the extra deaths during the outcome period
for patients with recurrent CDI may have resulted in an increase in costs attributable to recurrent CDI. Indeed, the attributable cost of recurrent CDI was only $8,709 when excluding patient deaths during the outcome period.
There are several limitations to this study. Most of the data
used in this study were administrative and collected electronically from hospital databases. Medical records were reviewed to confirm several of the most important variables in
this study (e.g., recurrent CDI status and postdischarge antibiotic use). Data on C. difficile strain type were not available,
so it was not possible to differentiate between CDI relapse
and reinfection.
The primary limitation of this study is the use of hospital
laboratory results to detect recurrent CDI cases. While we
identified all positive C. difficile toxin results from our hospital’s laboratory and reviewed charts to identify additional
CDI recurrences, we likely did not capture recurrent cases
that were identified and treated exclusively at other hospitals
or at outpatient clinics. These constitute 2 separate patient
groups. Bias due to exclusion of cases diagnosed at other
inpatient facilities should have been lessened since medical
records were reviewed to identify recurrent CDI cases diagnosed at other facilities and transferred to the study hospital
for treatment. Exclusion of recurrent CDI patients treated at
other inpatient facilities would likely lead to lower estimates
of attributable costs because those patients’ readmission costs

were not included in analyses. In contrast, exclusion of patients diagnosed and treated solely as outpatients may have
biased the population toward more severely ill recurrent CDI
patients who required hospitalization. In this case, the true
odds of zero costs may be lower than reported here. However,
the exclusion of outpatient recurrent CDI cases would not
impact the CRs given nonzero costs.
Recurrent CDI is known to be an important cause of continued morbidity after initial CDI. The results of this study,
which suggests that the attributable costs of a single recurrent
CDI case over 6 months are in excess of $11,000, should add
further impetus to the need for better prevention of and
treatment for recurrent CDI cases. This study also highlights
the need for additional research on recurrent CDI, specifically
with respect to the relationship between recurrent CDI and
mortality, the economic costs of recurrent CDI outside inpatient facilities, and the effect of recurrent CDI on quality
of life. Better methods of identifying patients at risk for recurrent CDI and preventing those recurrences would decrease
the economic burden of recurrent CDI.
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